Long-Acting Injectables Module 1

David Malebranche, MD, MPH; Raphael J. Landovitz, MD, MSC

Jointly provided by Postgraduate Institute for Medicine and Integritas Communications.


This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Target Audience

This activity is intended for HIV specialists engaged in the care of patients with HIV.

Program Description

Recent advances in antiretroviral therapy have led to the advent of long-acting injectables (LAIs) to treat HIV. Clinicians have many questions about safety, efficacy, and implementation, as well as questions about how best to select and educate patients. Dr. David Malebranche and Dr. Raphael Landovitz discuss a patient who may be a candidate for an LAI and address common questions about patient selection and education, oral lead-in, dosing considerations, missed doses, injection site reactions, and clinic protocols.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Tailor ART regimens according to patient comorbidities, risk factors, adverse events, and drug-drug interactions
  • Review recent data on new and emerging ART regimens


David Malebranche, MD, MPH
Internal Medicine Physician
Sexual Health/HIV Expert
Atlanta, Georgia

Raphael J. Landovitz, MD, MSC
Professor of Medicine
UCLA Center for Clinical AIDS Research & Education
Center Co-Director
Center for HIV Identification, Prevention, and Treatment Services (CHIPTS)
Core Co-Director
CHIPTS Combination Prevention Core
Los Angeles, California

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by PIM and Integritas Communications.  PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

David Malebranche, MD, MPH: Consulting Fees: Gilead Sciences, Inc., ViiV Healthcare Limited; Speakers’ Bureaus: Gilead Sciences, Inc.

Raphael J. Landovitz, MD, MSC: Consulting Fees: Cepheid, Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc.

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Instructions to Receive Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a minimum score of 100% on the posttest, and complete the program evaluation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

CME Questions – PIM Contact Information

For information about the accreditation of this program, please contact PIM via email at or at

Integritas Contact Information

For all other questions regarding this monograph, please contact Integritas via email at

System Requirements

Microsoft Windows 2000 SE or above.
Internet Explorer (v5.5 or greater), Chrome or Firefox MAC

MAC OS 10.2.8:
Internet Explorer is not supported on the Macintosh.

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

credit amount 0.25

credit type CME/CE

release 10/18/2021

expiration 10/18/2022

type Webcast Series